Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021798 | 0.90 | MAPT (0.36) | HTR2AHTR2CPTGS2HTR2B | |
| SCHEMBL1498964 | 0.90 | PSEN1 (0.35) | HTR2AHTR2CP2RX7KCNN4 | |
| SCHEMBL1498984 | 0.89 | BACE1 (0.36) | HTR2AHTR2CBACE1KCNN4HCAR3 | |
| SCHEMBL14975607 | 0.88 | P2RX7 (0.33) | HTR2AHTR2CP2RX7BACE1KCNN4 | |
| SCHEMBL1498818 | 0.86 | PTGS2 (0.32) | HTR2AHTR2CPTGS2HTR2B | |
| SCHEMBL1499074 | 0.84 | HTR2C (0.33) | HTR2AHTR2CP2RX7BACE1HTR2B | |
| SCHEMBL3662849 | 0.84 | DPP4 (0.35) | HTR2A | |
| SCHEMBL1498903 | 0.84 | HTR2A (0.39) | HTR2AHTR2CBACE1HTR2B | |
| SCHEMBL1498880 | 0.84 | BACE1 (0.41) | HTR2CBACE1HTR2B | |
| SCHEMBL6511952 | 0.81 | KCNN4 (0.40) | HTR2AHTR2CP2RX7KCNN4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | claimed |
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
| EP-2234488-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077443-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | HTR2A 2148/4885HTR2C 2198/4885P2RX7 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.